Revenue from Contracts with Customers (Tables)

6 Months Ended

Jun. 30, 2026

Revenue from Contract with Customer [Abstract]

The following table summarizes revenue by source as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2026		2025		2026		2025
Major Products /Service Lines
Product revenue, net(1)	$	376,933	$	374,547	$	746,782	$	741,465
License and royalty revenues		11,247		3,498		18,731		9,344
Total revenues	$	388,180	$	378,045	$	765,513	$	750,809

(1)

The Company’s product revenue includes PYLARIFY, Neuraceq, DEFINITY, and prior to January 1, 2026, TechneLite, among other products. TechneLite was sold in connection with the Company’s sale of its single-photon emission computerized tomography (“SPECT”) business to SHINE Technologies, LLC (“SHINE”), a wholly-owned subsidiary of Illuminated Holdings, Inc. (“Illuminated”), on January 1, 2026. This category represents the delivery of physical goods. The Company applies the same revenue recognition policies and judgments for all its principal products.

Revenue by product category on a net basis is as follows:


	Three Months Ended June 30,				Six Months Ended June 30,
(in thousands)	2026		2025		2026		2025
PYLARIFY	$	240,366	$	250,642	$	481,290	$	508,296
Total oncology		240,366		250,642		481,290		508,296
Neuraceq		39,616		—		75,055		—
Total neurology		39,616		—		75,055		—
DEFINITY		88,279		83,939		172,906		163,150
Total cardiology		88,279		83,939		172,906		163,150
Strategic partnerships and other		19,919		11,590		36,262		22,337
SPECT		—		31,874		—		57,026
Total revenues	$	388,180	$	378,045	$	765,513	$	750,809

Schedule of Revenue by Geographic Region Determined by Location of Customer or Other Party

The following table presents the Company’s revenue by geographic region determined by location of customer or other party for the periods presented:


	Three Months Ended June 30,										Six Months Ended June 30,
(in thousands)	2026		% of Revenue			2025		% of Revenue			2026		% of Revenue			2025		% of Revenue
United States	$	368,292		94.9	%	$	356,304		94.2	%	$	722,717		94.4	%	$	714,059		95.1	%
Rest of world		19,888		5.1	%		21,741		5.8	%		42,796		5.6	%		36,750		4.9	%
Total revenues	$	388,180		100.0	%	$	378,045		100.0	%	$	765,513		100.0	%	$	750,809		100.0	%

Schedule of Amount of and Change in Accruals for Rebate Liabilities

An analysis of the amount of, and change in, accruals for rebate liabilities is summarized as follows:


(in thousands)	Rebates
Balance at January 1, 2026	$	66,448
Provision related to current period revenues		105,315
Payments or credits made during the period		(101,299	)
Balance at June 30, 2026	$	70,464

Schedule of Deferred Revenue

The following table provides a roll forward of deferred revenue:


(in thousands)	Deferred Revenue
Balance at January 1, 2026	$	6,984
Revenue recognized in relation to the beginning of the year contract liability balance		(3,226	)
Revenue deferred		5,691
Balance at June 30, 2026	$	9,449